文献速递痛风与晶体性关节病

二甲双胍抑制mTOR通路减轻痛风尿酸钠晶体诱导的炎症与细胞死亡

mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
PubMed 文献 · Ann Rheum Dis · 2019-02-27

该转化研究从痛风患者离体免疫细胞出发,发现其mTOR通路表达升高,体外尿酸钠晶体刺激可模拟该现象,单核细胞为mTOR主要表达细胞。二甲双胍或雷帕霉素抑制mTOR可减少单核细胞死亡及促炎因子释放,且接受二甲双胍治疗的痛风患者发作频率较低,提示mTOR抑制可作为痛风附加治疗新靶点。

要点

  • 痛风患者离体免疫细胞mTOR通路表达升高,单核细胞最显著。
  • 尿酸钠晶体刺激单核细胞启动细胞死亡并释放多种促炎因子。
  • 二甲双胍或雷帕霉素抑制mTOR可减少细胞死亡和炎症介质释放。

核心结论

  • mTOR抑制是痛风治疗中值得关注的新治疗靶点。

研究设计与样本

  • 采用从离体到体外再回到体内的转化研究策略。
  • 离体检测痛风患者免疫细胞mTOR通路表达,体外以尿酸钠晶体刺激健康免疫细胞(B淋巴细胞、单核细胞、T淋巴细胞),并进行活细胞成像。
  • 体内观察接受mTOR抑制剂二甲双胍治疗的痛风患者发作频率。

主要发现

  • 痛风患者离体免疫细胞mTOR通路表达高于对照,体外尿酸钠晶体刺激健康免疫细胞可模拟该升高。
  • 单核细胞是mTOR最显著表达细胞,遇尿酸钠晶体后启动细胞死亡并释放多种促炎因子。
  • 二甲双胍或雷帕霉素抑制mTOR信号后,细胞死亡和炎症介质释放减少。
  • 接受二甲双胍治疗的痛风患者痛风发作频率较低。

临床怎么用

  • 对合并心血管或代谢疾病的痛风患者,二甲双胍等mTOR抑制剂可能同时靶向炎症与共病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases. The inflammation is caused by the deposition of monosodium urate (MSU) crystals in tissues, especially in the joints, triggering immune cells to mount an inflammatory reaction. Recently, it was shown that MSU crystals can induce mechanistic target of rapamycin (mTOR) signalling in monocytes encountering these crystals in vitro. The mTOR pathway is strongly implicated in cardiovascular and metabolic disease. We hypothesised that inhibiting this pathway in gout might be a novel avenue of treatment in these patients, targeting both inflammation and comorbidities. METHODS: We used a translational approach starting from ex vivo to in vitro and back to in vivo. RESULTS: We show that ex vivo immune cells from patients with gout exhibit higher expression of the mTOR pathway, which we can mimic in vitro by stimulating healthy immune cells (B lymphocytes, monocytes, T lymphocytes) with MSU crystals. Monocytes are the most prominent mTOR expressers. By using live imaging, we demonstrate that monocytes, on encountering MSU crystals, initiate cell death and release a wide array of proinflammatory cytokines. By inhibiting mTOR signalling with metformin or rapamycin, a reduction of cell death and release of inflammatory mediators was observed. Consistent with this, we show that patients with gout who are treated with the mTOR inhibitor metformin have a lower frequency of gout attacks. CONCLUSIONS: We propose mTOR inhibition as a novel therapeutic target of interest in gout treatment.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019. PMID: 30814053. doi:10.1136/annrheumdis-2018-214656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。